Will BioMarin’s (BMRN) Raised Outlook After Solid Revenue Growth Shift Its Investment Narrative?

• BioMarin Pharmaceutical recently presented at the Jefferies London Healthcare Conference 2025 in London, following its announcement of a 4.1% year-over-year revenue increase to US$776.1 million driven by strong growth in key therapies.
• The company also raised its full-year guidance more than industry peers despite a softer overall quarter, highlighting renewed operational momentum in its Enzyme Therapies and Skeletal Conditions business units.
• We'll explore how BioMarin Pharmaceutical’s decision to raise guidance after robust sales growth in core products impacts its investment narrative.

Rare earth metals are the new gold rush. Find out which 36 stocks are leading the charge.

BioMarin Pharmaceutical Investment Narrative Recap

To be a BioMarin Pharmaceutical shareholder, you need to believe that the company's therapies for rare diseases can continue to deliver durable growth and maintain their competitive edge. The recent decision to raise full-year guidance despite a mixed quarter provides some reassurance about the near-term outlook for revenue from VOXZOGO and PALYNZIQ, though it does not fundamentally change the risk that rising R&D and SG&A costs remain the biggest short-term headwind for margin expansion.

Among recent announcements, the FDA’s acceptance of a Priority Review for PALYNZIQ in adolescents stands out as particularly relevant for the growth catalysts tied to expanded indications. While positive for market reach and future revenue, this milestone underlines the importance of regulatory momentum and new patient populations for supporting BioMarin’s core investment thesis.

However, investors should also keep in mind that, contrasted with these growth stories, portfolio concentration risk in just a few drugs leaves BioMarin vulnerable if…

Read the full narrative on BioMarin Pharmaceutical (it's free!)

BioMarin Pharmaceutical's outlook anticipates $3.8 billion in revenue and $1.1 billion in earnings by 2028. Achieving this would require 7.6% annual revenue growth and a $442.8 million increase in earnings from the current $657.2 million.

Uncover how BioMarin Pharmaceutical's forecasts yield a $90.50 fair value, a 63% upside to its current price.

Exploring Other Perspectives

Fair value estimates from four Simply Wall St Community members span US$83.91 to US$144.30, reflecting a wide spectrum of market views. As you weigh these differences, remember that BioMarin’s earnings growth prospects are considered high but remain sensitive to concentrated product risks and regulatory milestones.

Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth just $83.91!

Build Your Own BioMarin Pharmaceutical Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com